Antidiabetic agents and endothelial dysfunction - beyond glucose control.
about
Insulin Resistance and Endothelial Dysfunction Constitute a Common Therapeutic Target in Cardiometabolic DisordersThe pattern of circulating microparticles in patients with diabetes mellitus with asymptomatic atherosclerosis.Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study.High Glucose Stimulates Expression of MFHAS1 to Mitigate Inflammation via Akt/HO-1 Pathway in Human Umbilical Vein Endothelial Cells.Long-term Saxagliptin Treatment Improves Endothelial Function but not Pulse Wave Velocity and Intima-Media Thickness in Type 2 Diabetic Patients.
P2860
Antidiabetic agents and endothelial dysfunction - beyond glucose control.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Antidiabetic agents and endothelial dysfunction - beyond glucose control.
@en
type
label
Antidiabetic agents and endothelial dysfunction - beyond glucose control.
@en
prefLabel
Antidiabetic agents and endothelial dysfunction - beyond glucose control.
@en
P2860
P356
P1476
Antidiabetic agents and endothelial dysfunction - beyond glucose control.
@en
P2093
Linnéa Eriksson
Thomas Nyström
P2860
P356
10.1111/BCPT.12402
P577
2015-04-19T00:00:00Z